Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2026
5 min

Dupilumab in CRSwNP: From Evidence to Practice

Author: Sanofi

Editorial Team

On June 4th 2026, Sanofi & Regeneron brought together a leading clinical expert for a virtual webinar exploring innovative approaches to Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Our featured speaker, Professor Claire Hopkins, Consultant ENT Surgeon at Guy’s & St Thomas’ Hospitals, shared valuable insights on advancing patient care and treatment outcomes. Each video dives into key topics such as treatment strategies, real-world experiences, and evolving standards of care.
Prescribing Information

Discover key insights from the webinar by watching the video clips below.

The Role of Type 2 Inflammation in CRSwNP

Watch Prof Hopkins describe the substantial disease burden of CRSwNP, the role of type 2 inflammation, and the limitations of repeated systemic corticosteroids and sinus surgery. 

DUPIXENT (dupilumab) in CRSwNP: Clinical Evidence & Patient Outcomes

Watch Prof Hopkins explore clinical trials’ and real-world evidence showing DUPIXENT’s impact on key outcomes in severe CRSwNP, including nasal polyps, congestion, sense of smell, and the need for further surgery.

Navigating Patient Pathways: Treatment Decisions with DUPIXENT (dupilumab)

Watch Prof Hopkins explain how to identify and manage patients with severe uncontrolled CRSwNP who may be eligible for DUPIXENT, covering reimbursement clinical assessment, practical initiation and follow-up.

MAT-XU-2603399 (v1.0) Date of preparation: November 2026  

Related Content